Skip to main content
. 2021 Oct 1;131(19):e150211. doi: 10.1172/JCI150211

Figure 1. Schematic of the clinical study.

Figure 1

The clinical trial was divided into 4 parts: blood drawing and CAR T cell preparation, CAR T cell infusion, ATI, and ART reinitiation after viral rebound. The safety laboratory values and HIV-1 viral load were monitored at regular intervals throughout the study.